June Editors’ Picks from AACR Journals
Back for the month of June are the editors’ picks from the eight scientific journals published by the American...
Back for the month of June are the editors’ picks from the eight scientific journals published by the American...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
While COVID-19 is at the center of medical news, important cancer research findings continue to be reported. As March...
In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for...
Every month, the editors from the portfolio of scientific journals published by the AACR select one “must read” article...
During the early part of summer 2018, the U.S. Food and Drug Administration (FDA) has approved several new anticancer...
Highlights from a workshop and journal article that shared key considerations for including overall survival as an endpoint in...
In the midst of the dog days of summer, the U.S. Food and Drug Administration (FDA) has provided good...
Early detection of most cancers is an elusive and daunting task; nevertheless, it has remained a top priority for...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris)...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the...
Pancreatic cancer remains a challenging disease to treat, with a five-year survival rate of less than 9 percent, according...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...
As a predoctoral student in the Integrated Biomedical Sciences Graduate Program at The Ohio State University in 2005, Bethany...
Thirty years ago, Mary-Claire King, PhD, FAACR, and colleagues were the first to demonstrate that breast cancer could be genetically inherited....
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
To kick off the new year, the editors of the 10 AACR journals highlighted two phase I clinical trials,...
Guest post by the Biopharma Collaborative Core Team In 2019, AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) embarked...
Early detection is key to improving outcomes from cancer. Shifting the focus even earlier in the natural history of...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
By Nicholas Warren, PhD On Thursday, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) announced...
Grab a cold drink and escape the midsummer heat with July’s rendition of Editors’ Picks. This month, the editors...
Ten years ago, then-President of the AACR, Tyler Jacks, PhD, FAACR, conceived the idea for a “comprehensive, high-impact journal that would present new...
In the United States, nearly 24,000 people are estimated to receive a brain or nervous system cancer diagnosis in 2020....
As we welcome the fall season, it’s time for our September edition of Editors’ Picks, a monthly collection of...
The cover of the inaugural issue of Blood Cancer Discovery, launched in July 2020, does not feature stained tissue...
The new year has already ushered in some changes, but one thing stays the same. Each month, we’ll continue to feature the “must read” articles handpicked by the editors...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
Immunotherapy has revolutionized cancer treatment over the past decade, providing potentially lifesaving therapies to many patients who otherwise would have limited options. Despite its success...